Indacaterol
- Generic Name
- Indacaterol
- Brand Names
- Hirobriz, Onbrez, Ultibro, Oslif Breezhaler, Hirobriz Breezhaler, Onbrez Breezhaler
- Drug Type
- Small Molecule
- Chemical Formula
- C24H28N2O3
- CAS Number
- 312753-06-3
- Unique Ingredient Identifier
- 8OR09251MQ
- Background
Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease. It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as Onbrez and in America as Arcapta Neohal...
- Indication
For the long term, once-daily-dosing maintenance of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
- Associated Conditions
- Asthma, Chronic Obstructive Pulmonary Disease (COPD)
- Associated Therapies
- Maintenances
Efficacy of Indacaterol 150 µg Versus Formoterol
- Conditions
- Interventions
- First Posted Date
- 2011-06-21
- Last Posted Date
- 2017-04-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT01377428
To Determine the Relationship Between Baseline Reversibility and the Efficacy of Indacaterol
- Conditions
- Interventions
- First Posted Date
- 2011-01-07
- Last Posted Date
- 2016-11-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 625
- Registration Number
- NCT01272362
- Locations
- 🇫🇷
Novartis Investigative Site, Villefranche sur Saone, France
12-week Open-label Evaluation of Efficacy and Safety of Indacaterol
- Conditions
- Interventions
- First Posted Date
- 2010-11-02
- Last Posted Date
- 2013-11-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 90
- Registration Number
- NCT01232894
- Locations
- 🇮🇱
Novartis Investigative Site, Tel Aviv, Israel
Efficacy, Safety and Pharmacokinetics of Different Regimens of Indacaterol
- Conditions
- Interventions
- First Posted Date
- 2010-07-05
- Last Posted Date
- 2011-08-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 191
- Registration Number
- NCT01156844
- Locations
- 🇺🇸
Novartis Investigator Site, Oklahoma City, Oklahoma, United States
🇬🇧Novartis Investigative Site, Merthyr Tydfil, United Kingdom
Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Interventions
- First Posted Date
- 2010-03-18
- Last Posted Date
- 2011-08-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 552
- Registration Number
- NCT01089127
- Locations
- 🇺🇸
Novartis Investigative Site, Richmond, Virginia, United States
🇺🇸Novartis Investigator Site, Tacoma, Washington, United States
🇺🇸Novartis Investigative site, Newport News, Virginia, United States
Efficacy and Safety of Different Doses of Indacaterol
- Conditions
- Interventions
- First Posted Date
- 2010-03-02
- Last Posted Date
- 2011-08-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 511
- Registration Number
- NCT01079130
- Locations
- 🇺🇸
Novartis Investigative site, North Charleston, South Carolina, United States
🇺🇸Novartis Investigator Site, Seattle, Washington, United States
🇺🇸Novartis Investigative Site, Charleston, South Carolina, United States
Comparison of Efficacy of Indacaterol Versus Placebo Over 12 Weeks
- Conditions
- Interventions
- First Posted Date
- 2010-02-15
- Last Posted Date
- 2011-08-19
- Lead Sponsor
- Novartis
- Target Recruit Count
- 318
- Registration Number
- NCT01068600
- Locations
- 🇺🇸
Novartis Investigator Site, McKinney, Texas, United States
🇺🇸Novartis Investigative Site, Richmond, Virginia, United States
🇺🇸Novartis Investigative site, Greenville, South Carolina, United States
Effect of Indacaterol on Inspiratory Capacity (IC)
- Conditions
- Interventions
- First Posted Date
- 2009-11-13
- Last Posted Date
- 2016-02-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 173
- Registration Number
- NCT01012765
- Locations
- 🇩🇪
Novartis Investigative site, Leipzig, Germany
🇩🇪Novartis Investigative Site, Zerbst, Germany
🇩🇪Novartis Investigator Site, Witten, Germany
Safety, Tolerability and Efficacy of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
- First Posted Date
- 2008-05-15
- Last Posted Date
- 2011-08-22
- Lead Sponsor
- Novartis
- Target Recruit Count
- 415
- Registration Number
- NCT00677807
- Locations
- 🇹🇷
Novartis Investigative Site, Kartal/Istanbul, Turkey
🇺🇸Novartis Investigative SIte, Fullerton, California, United States
🇹🇷Novartis Investigator Site, Yenisehir/Izmir, Turkey
Study to Determine the Onset of Action of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
- First Posted Date
- 2008-04-30
- Last Posted Date
- 2011-09-12
- Lead Sponsor
- Novartis
- Target Recruit Count
- 89
- Registration Number
- NCT00669617
- Locations
- 🇭🇺
Novartis Investigative site, Deszk, Hungary
🇭🇺Novartis Investigative Site, Nyiregyhaza, Hungary
🇩🇪Novartis Investigator Site, Potsdam, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.